SciELO - Scientific Electronic Library Online

 
vol.34 número3Clinical reasoning in medicine I: A historical journeyRole gof thrombopoietin stimulating agents (Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Iatreia

versão impressa ISSN 0121-0793

Resumo

SAAVEDRA-CHACON, María Fernanda; PEREZ, Santiago  e  GUEVARA, Luis Gonzalo. Metabolic associated fatty liver disease. A new proposal for a disease on the rise. Iatreia [online]. 2021, vol.34, n.3, pp.241-252.  Epub 02-Ago-2021. ISSN 0121-0793.  https://doi.org/10.17533/udea.iatreia.101.

Nonalcoholic fatty liver disease is characterized by fat accumulation in the liver exceeding 5% of its weight. The spectrum of the disease includes fatty liver, steatohepatitis and progressive fibrosis leading to cirrhosis. It is also possible to develop hepatocellular carcinoma even without cirrhosis. Its physiopathology highlights the metabolic component of the disease, being acknowledged as a hepatic expression of a multisystemic metabolic disorder.

Fat accumulation causes apoptosis, inflammation and fibrosis. In the view of the rising research on the subject, a new terminology is being proposed, consisting in metabolic associated fatty liver disease, now perceived as a standalone condition not needing the exclusion of other entities to make a diagnosis.

The diagnosis includes the identification of liver steatosis and fibrosis, as a prognosis marker, using imaging studies and scoring models with biochemical markers. Treatment consists primarily in weight reduction and improving the metabolic baseline condition. New studies seeking pharmacologic interventions targeting hepatic inflammation are being conducted. Therapy also includes appropriate management of other medical comorbidities and cardiovascular risk control.

Palavras-chave : Cancer of Liver; Fatty Liver; Liver Cirrhosis; Metabolic syndrome.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )